» Articles » PMID: 24472629

Loss of GABAergic Cortical Neurons Underlies the Neuropathology of Lafora Disease

Overview
Journal Mol Brain
Publisher Biomed Central
Date 2014 Jan 30
PMID 24472629
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lafora disease is an autosomal recessive form of progressive myoclonic epilepsy caused by defects in the EPM2A and EPM2B genes. Primary symptoms of the pathology include seizures, ataxia, myoclonus, and progressive development of severe dementia. Lafora disease can be caused by defects in the EPM2A gene, which encodes the laforin protein phosphatase, or in the NHLRC1 gene (also called EPM2B) codifying the malin E3 ubiquitin ligase. Studies on cellular models showed that laforin and malin interact and operate as a functional complex apparently regulating cellular functions such as glycogen metabolism, cellular stress response, and the proteolytic processes. However, the pathogenesis and the molecular mechanism of the disease, which imply either laforin or malin are poorly understood. Thus, the aim of our study is to elucidate the molecular mechanism of the pathology by characterizing cerebral cortex neurodegeneration in the well accepted murine model of Lafora disease EPM2A-/- mouse.

Results: In this article, we want to asses the primary cause of the neurodegeneration in Lafora disease by studying GABAergic neurons in the cerebral cortex. We showed that the majority of Lafora bodies are specifically located in GABAergic neurons of the cerebral cortex of 3 months-old EPM2A-/- mice. Moreover, GABAergic neurons in the cerebral cortex of younger mice (1 month-old) are decreased in number and present altered neurotrophins and p75NTR signalling.

Conclusions: Here, we concluded that there is impairment in GABAergic neurons neurodevelopment in the cerebral cortex, which occurs prior to the formation of Lafora bodies in the cytoplasm. The dysregulation of cerebral cortex development may contribute to Lafora disease pathogenesis.

Citing Articles

H and P magnetic resonance spectroscopy reveals potential pathogenic and biomarker metabolite alterations in Lafora disease.

Chan K, Panatpur A, Messahel S, Dahshi H, Johnson T, Henning A Brain Commun. 2024; 6(2):fcae104.

PMID: 38585668 PMC: 10998360. DOI: 10.1093/braincomms/fcae104.


Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model.

Donohue K, Fitzsimmons B, Bruntz R, Markussen K, Young L, Clarke H Neurotherapeutics. 2023; 20(6):1808-1819.

PMID: 37700152 PMC: 10684475. DOI: 10.1007/s13311-023-01434-9.


Role of Astrocytes in the Pathophysiology of Lafora Disease and Other Glycogen Storage Disorders.

Duran J Cells. 2023; 12(5).

PMID: 36899857 PMC: 10000527. DOI: 10.3390/cells12050722.


Glial Contributions to Lafora Disease: A Systematic Review.

Della Vecchia S, Marchese M, Santorelli F Biomedicines. 2022; 10(12).

PMID: 36551859 PMC: 9776290. DOI: 10.3390/biomedicines10123103.


Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model.

Molla B, Heredia M, Campos A, Sanz P Mol Neurobiol. 2022; 59(10):6018-6032.

PMID: 35835895 PMC: 9463199. DOI: 10.1007/s12035-022-02956-7.


References
1.
Chan E, Bulman D, Paterson A, Turnbull J, Andermann E, Andermann F . Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22. J Med Genet. 2003; 40(9):671-5. PMC: 1735578. DOI: 10.1136/jmg.40.9.671. View

2.
Gentry M, Roma-Mateo C, Sanz P . Laforin, a protein with many faces: glucan phosphatase, adapter protein, et alii. FEBS J. 2012; 280(2):525-37. PMC: 3371293. DOI: 10.1111/j.1742-4658.2012.08549.x. View

3.
Kenchappa R, Tep C, Korade Z, Urra S, Bronfman F, Yoon S . p75 neurotrophin receptor-mediated apoptosis in sympathetic neurons involves a biphasic activation of JNK and up-regulation of tumor necrosis factor-alpha-converting enzyme/ADAM17. J Biol Chem. 2010; 285(26):20358-68. PMC: 2888447. DOI: 10.1074/jbc.M109.082834. View

4.
Yokoi S, Austin J, Witmer F, Sakai M . Studies in myoclonus epilepsy (Lafora body form). I. Isolation and preliminary characterization of Lafora bodies in two cases. Arch Neurol. 1968; 19(1):15-33. DOI: 10.1001/archneur.1968.00480010033002. View

5.
Puri R, Suzuki T, Yamakawa K, Ganesh S . Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. J Biol Chem. 2009; 284(34):22657-63. PMC: 2755673. DOI: 10.1074/jbc.M109.009688. View